Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Cox

Showing results (741-750 of 757) with videos related to

Pageof 76
Sort By:
Molecular Therapy. Methods & Clinical Development|September 13, 2016
Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adultsGaudensia Mutua, Bashir Farah, Robert Langat, et al.
European Journal of Medical Genetics|February 6, 2010
Interstitial microduplication of Xp22.31: Causative of intellectual disability or benign copy number variant?Feng Li, Yiping Shen, Udo Köhler, et al.
The Journal of Infectious Diseases|January 19, 2010
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)Hannah Kibuuka, Robert Kimutai, Leonard Maboko, et al.
Open Forum Infectious Diseases|August 21, 2024
Reflex Xpert MTB/XDR Testing of Residual Rifampicin-Resistant Specimens: A Clinical Laboratory-Based Diagnostic Accuracy and Feasibility Study in South AfricaC M Centner, R Munir, E Tagliani, et al.
Plos One|August 8, 2012
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adultsMichael C Keefer, Jill Gilmour, Peter Hayes, et al.
Plos One|December 24, 2010
Equivalence of ELISpot assays demonstrated between major HIV network laboratoriesDilbinder K Gill, Yunda Huang, Gail L Levine, et al.
The Journal of Infectious Diseases|January 13, 2017
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost RegimensJulien Nyombayire, Omu Anzala, Brian Gazzard, et al.
Plos One|May 24, 2011
In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteersSandhya Vasan, Arlene Hurley, Sarah J Schlesinger, et al.
The Lancet. Infectious Diseases|May 14, 2022
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trialEmily E Coates, Srilatha Edupuganti, Grace L Chen, et al.
Clinical and Vaccine Immunology : CVI|December 19, 2008
Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continentsMark J Boaz, Peter Hayes, Tony Tarragona, et al.
Pageof 76

Showing results (741-750 of 757) with videos related to

Sort By:
Pageof 76
Molecular Therapy. Methods & Clinical Development|September 13, 2016
Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adultsGaudensia Mutua, Bashir Farah, Robert Langat, et al.
European Journal of Medical Genetics|February 6, 2010
Interstitial microduplication of Xp22.31: Causative of intellectual disability or benign copy number variant?Feng Li, Yiping Shen, Udo Köhler, et al.
The Journal of Infectious Diseases|January 19, 2010
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)Hannah Kibuuka, Robert Kimutai, Leonard Maboko, et al.
Open Forum Infectious Diseases|August 21, 2024
Reflex Xpert MTB/XDR Testing of Residual Rifampicin-Resistant Specimens: A Clinical Laboratory-Based Diagnostic Accuracy and Feasibility Study in South AfricaC M Centner, R Munir, E Tagliani, et al.
Plos One|August 8, 2012
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adultsMichael C Keefer, Jill Gilmour, Peter Hayes, et al.
Plos One|December 24, 2010
Equivalence of ELISpot assays demonstrated between major HIV network laboratoriesDilbinder K Gill, Yunda Huang, Gail L Levine, et al.
The Journal of Infectious Diseases|January 13, 2017
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost RegimensJulien Nyombayire, Omu Anzala, Brian Gazzard, et al.
Plos One|May 24, 2011
In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteersSandhya Vasan, Arlene Hurley, Sarah J Schlesinger, et al.
The Lancet. Infectious Diseases|May 14, 2022
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trialEmily E Coates, Srilatha Edupuganti, Grace L Chen, et al.
Clinical and Vaccine Immunology : CVI|December 19, 2008
Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continentsMark J Boaz, Peter Hayes, Tony Tarragona, et al.
Pageof 76